Selective PARP Inhibitor Improves Survival in Breast Cancer Trial
American Association for Cancer Research
Saruparib has higher selectivity for PARP1, improving safety and tolerability compared to existing first-gen PARP inhibitors
Innovative approach integrates genetic data to identify drug targets with high potential for clinical trial success